US · CMMB
Chemomab Therapeutics Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tel Aviv 6158002
- Website
- chemomab.com
Price · as of 2024-12-31
$1.61
Market cap 11.45M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $493.76 | ||||
| 2019 | $58.24 | ||||
| 2020 | $282.24 | ||||
| 2021 | $16.80 | ||||
| 2022 | $5.92 | ||||
| 2023 | $3.10 | ||||
| 2024 | $5.00 |
AI valuation
Our deep-learning model estimates Chemomab Therapeutics Ltd.'s (CMMB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.61
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CMMB | Chemomab Therapeutics Ltd… | $1.61 | 11.45M | — | — | — | — | -1.60 | 1.66 | — | -0.61 | — | 1.66 | 0.00% | — | — | -91.77% | 1052.79% | -71.64% | 0.02 | — | 4.98 | 4.51 | 0.41 | -6204.00% | — | -3437.00% | -68.89% | -4.80 | 1104.22% | 0.00% | 0.00% | 0.00% | -0.58 | -0.55 | — | -6.50 |
| BIVI | BioVie Inc. | $1.38 | 10.41M | — | — | — | — | -0.15 | 0.14 | — | 0.86 | — | 0.14 | 0.00% | — | — | -101.64% | 8838.56% | -75.01% | 0.02 | -54.30 | 9.10 | 8.64 | 1.01 | -8341.00% | — | -3192.00% | -740.10% | -8.36 | 9307.74% | 0.00% | 0.00% | 0.00% | 0.81 | 0.77 | — | -24.00 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| GLMD | Galmed Pharmaceuticals Lt… | $0.61 | 3.35M | — | — | — | — | -0.23 | 0.11 | — | 1.83 | — | 0.11 | 0.00% | — | — | -49.77% | -552.15% | -42.80% | 0.00 | -418.53 | 7.42 | 7.15 | 0.63 | -7302.00% | — | -419.00% | -334.59% | -2.71 | -517.15% | 0.00% | 0.00% | 104.25% | 2.16 | 2.31 | — | -14.90 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| XRTX | XORTX Therapeutics Inc. | $0.41 | 1.55M | — | — | — | — | -0.75 | 0.97 | — | -0.37 | — | 1.07 | 0.00% | — | — | -119.80% | -346.54% | -95.46% | 0.02 | — | 1.61 | 1.58 | 0.26 | -5273.00% | — | 398.00% | -139.13% | -4.71 | -294.67% | 0.00% | 0.00% | 0.00% | -0.36 | -0.43 | — | -14.31 |
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
- CEO
- Adi Mor George
- Employees
- 20
- Beta
- 0.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.61) − 1 = — (DCF, example).